WHAT IS CLAIMED IS:

1. Use of an antibody or antigen-binding fragment thereof that specifically binds to a *Staphylococcus aureus* (*S. aureus*) alpha toxin antigen in the manufacture of a medicament for treating or preventing a polybacterial infection in a patient, wherein the antibody or antigen-binding fragment thereof ~~that specifically binds to a *Staphylococcus aureus* (*S. aureus*) antigen~~ is to be administered to the patient, wherein the polybacterial infection comprises *S. aureus* and at least one gram-negative~~other~~ bacterium, wherein the *S. aureus* alpha toxin potentiates the growth of the at least one gram-negative bacterium; and wherein the antibody or antigen-binding fragment thereof that binds to *S. aureus* alpha toxin binds to the same alpha toxin epitope as an antibody comprising the VH and VL sequences of SEQ ID NOs: 45 and 46.

~~2. The use of claim 1, wherein the *S. aureus* potentiates the growth of the at least one other bacterium in the patient.~~

~~3. The use of claim 1 or 2, wherein the administration inhibits the growth of the at least one other bacterium.~~

~~4.~~2. The use of ~~any one of claims 1-3~~claim 1, wherein the at least one gram-negative ~~other~~ bacterium is *Pseudomonas*, *Klebsiella* or *Acinetobacter*.

~~5.~~3. The use of claim ~~4~~2, wherein the *Pseudomonas* is *Pseudomonas aeruginosa* (*P. aeruginosa*), the *Klebsiella* is *Klebsiella pneumonia*e (*K. pneumoniae*) or the *Acinetobacter* is *Acinetobacter baumannii* (*A. baumannii*).

~~6. Use of an antibody or antigen-binding fragment thereof in the manufacture of a medicament for treating or preventing a polybacterial infection in a patient, wherein the antibody or antigen-binding fragment thereof that specifically binds to a *P. aeruginosa* antigen is to be administered to the patient, wherein the polybacterial infections comprises *P. aeruginosa* and at least one other bacterium.~~

~~7. The use of claim 6, wherein the *P. aeruginosa* potentiates the growth of the at least one other bacterium in the patient.~~

~~8. The use of claim 6 or 7, wherein the administration inhibits the growth of the at least one other bacterium.~~

~~9. The use of any one of claims 6-8, wherein the at least one other bacterium is *Staphylococcus*, *Klebsiella* or *Acinetobacter*.~~

~~10. The use of claim 9, wherein the at least one other bacterium is *S. aureus*, *K. pneumoniae* or *A. baumannii*.~~

~~11.~~4. Use of an antibody or antigen-binding fragment thereof that specifically binds to *S. aureus* alpha toxin in the manufacture of a medicament for inhibiting the growth of *P. aeruginosa* in a patient, wherein the ~~-~~antibody or antigen-binding fragment thereof that specifically binds to a *S. aureus* antigen is to be administered to the patient; and wherein the antibody or antigen-binding fragment thereof that binds to *S. aureus* alpha toxin binds to the same alpha toxin epitope as an antibody comprising the VH and VL sequences of SEQ ID NOs: 45 and 46.

~~12. Use of an antibody or antigen-binding fragment thereof in the manufacture of a medicament for reducing *S. aureus* colony-forming units (CFU) in a patient, wherein the antibody or antigen-binding fragment thereof that specifically binds to a *Pseudomonas aeruginosa* antigen is to be administered to the patient.~~

~~13. The use of any one of claims 1-5 or 11, wherein the *S. aureus* antigen is alpha toxin.~~

~~14. The use of claim 13, wherein the antibody or antigen-binding fragment thereof that binds to *S. aureus* alpha toxin binds to the same alpha toxin epitope as an antibody comprising the VH and VL sequences of SEQ ID NOs:20 and 19; SEQ ID NOs; 22 and 21; SEQ ID NOs:24 and 23; SEQ ID NOs:26 and 25; SEQ ID NOs:28 and 27; SEQ ID NOs:29 and 30;~~

~~SEQ ID NOs:31 and 32; SEQ ID NOs:33 and 34; SEQ ID NOs:35 and 36; SEQ ID NOs:37 and 38; SEQ ID NOs:39 and 40; SEQ ID NOs:41 and 42; SEQ ID NOs:43 and 44; SEQ ID NOs:45 and 46; SEQ ID NOs:47 and 48; SEQ ID NOs:49 and 46; SEQ ID NOs:50 and 46; SEQ ID NOs:50 and 51; or SEQ ID NOs:67 and 51.~~

~~15. The use of claim 13, wherein the antibody or antigen-binding fragment thereof that binds to *S. aureus* alpha toxin is an antibody or antigen-binding fragment thereof comprising (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO:7, 10, 13, or 57; (b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO:8, 11, 14, 17, 58 or 63; (c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO:9, 12, 15, 18, 16, 53, 54, 55, 66, 59, 60 or 64; (d) a VL CDR1 comprising the amino acid sequence of SEQ ID NO:1 or 4; (e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO:2, 5, 61 or 65; and (f) a VL CDR3 comprising the amino acid sequence of SEQ ID NO:3, 6, 52, 56 or 62.~~

~~16.~~5. The use of <u>any one of</u> claim<u>s 1-4</u> ~~13~~, wherein the antibody or antigen-binding fragment thereof comprises the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 sequences of ~~SEQ ID NOs:7, 8, 9, 1, 2 and 3; SEQ ID NOs:10, 11, 12, 1, 2 and 3; SEQ ID NOs:13, 14, 15, 4, 5 and 6; SEQ ID NOs:7, 17, 18, 1, 2 and 3; SEQ ID NOs:7, 8, 16, 1, 2 and 52; SEQ ID NOs:7, 8, 53, 1, 2 and 52; SEQ ID NOs; 7, 8, 54, 1, 2 and 52; SEQ ID NOs:7, 8, 55, 1, 2 and 56; SEQ ID NOs:7, 8, 55, 1, 2 and 52; SEQ ID NOs:7, 8, 66, 1, 2 and 52; SEQ ID NOs:7, 8, 53, 1, 2 and 56;~~ SEQ ID NOs:57, 58, 59, 1, 2 and 56~~; SEQ ID NOs:7, 8, 60, 1, 61 and 62; SEQ ID NOs:57, 63, 59, 1, 2 and 56; SEQ ID NOs:57, 63, 64, 1, 2 and 56; SEQ ID NOs:57, 63, 64, 1, 65 and 62; or SEQ ID NOs:57, 58, 59, 1, 65 and 67~~.

~~17.~~6. The use of claim ~~13~~5, wherein antibody or antigen-binding fragment thereof ~~that binds to *S. aureus* alpha toxin binds to the same alpha toxin epitope as an antibody comprising~~ <u>comprises</u> the VH and VL sequences of SEQ ID NOs:45 and 46.

<u>7. The use of claim 5, wherein the antibody or antigen-binding fragment thereof that specifically binds to *S. aureus* alpha toxin comprises a heavy chain comprising the amino</u>

acid sequence of SEQ ID NO: 68 and a light chain comprising the amino acid sequence of SEQ ID NO:69.

8. The use of any one of claims 1-5, wherein the antibody of antigen-binding fragment thereof is an IgG antibody of antigen-binding fragment thereof.

9. The use of claim 8, wherein the IgG antibody comprises the YTE substitutions of M252Y, S254T, and T256E, wherein the numbering is according to the EU index.

~~18. The use of any one of claims 6-10 or 12, wherein the *P. aeruginosa* antigen is Psl, PcrV, or both Psl and PcrV.~~

~~19. The use of claim 18, wherein the antibody or antigen-binding fragment thereof binds to *P. aeruginosa* Psl and PcrV.~~

~~20. The use of claim 18 or 19, wherein the antibody or antigen-binding fragment thereof comprises the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 sequences of SEQ ID NOs:73, 74, 80, 76, 77, and 78 or SEQ ID NOs: 73, 74, 94, 76, 77, and 95.~~

~~21. The use of claim 18 or 19, wherein the antibody or antigen-binding fragment thereof comprises the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 sequences of SEQ ID NOs:83, 84, 85, 86, 87, and 88.~~

~~22. The use of claim 18 or 19, wherein the antibody or antigen-binding fragment thereof comprises the VH sequence of SEQ ID NO:79 and the VL sequence of SEQ ID NO:72.~~

~~23. The use of claim 18 or 19, wherein the antibody or antigen-binding fragment thereof comprises the VH sequence of SEQ ID NO:81 and the VL sequence of SEQ ID NO:82.~~

~~24.~~10. The use of any one of claims 1-~~9~~10, wherein the polybacterial infection is an ocular infection, a lung infection, a burn infection, a wound infection, a surgical wound infection, a skin infection, a soft tissue infection, a blood infection, a bone infection, or a combination of two or more of said infections.

~~25.~~11. The use of any one of claims 1-10~~24~~, wherein the patient has acute pneumonia, burn injury, corneal infection, cystic fibrosis, ventilator-associated pneumonia, a skin infection, a wound infection, or a combination thereof.

12. The use of any one of claims 1-11, wherein the polybacterial infection is a nosocomial infection.